Personalis (PSNL) Q4 2025 earnings review
Clinical Volumes Explode, But Profitability Takes a Backseat
Personalis has successfully completed its strategic pivot toward clinical diagnostics, evidenced by a massive 329% YoY surge in Q4 clinical test volume. The company secured pivotal Medicare coverage for breast and lung cancer, removing the biggest overhang on the stock. However, this hypergrowth strategy comes at a severe cost to margins. Because the company is aggressively pushing NeXT Personal volume ahead of full reimbursement, 2026 gross margins are guided to a dismal 15-20%, and cash burn is accelerating to $100M. The fortified $240M balance sheet provides runway, but investors are now financing a costly land-grab in the MRD space.
🐂 Bull Case
Securing Medicare coverage for breast cancer surveillance in Q4 and NSCLC in Q1 2026 represents the most critical milestone for the company. This transitions NeXT Personal from a highly-subsidized R&D tool into a monetizable clinical asset.
Clinical test volume grew sequentially every single quarter in 2025, reaching 16,233 tests for the year (nearly 400% YoY growth). The market is clearly responding to the ultra-sensitive 1-part-per-million detection capability.
🐻 Bear Case
Delivering tens of thousands of tests before broad reimbursement is devastating gross margins. FY26 gross margin is guided to 15-20%, down from the mid-30% range seen in early 2024, reflecting the heavy cost of goods for scaling the clinical footprint.
Guided cash usage of $100M in FY26 represents a significant step up from the ~$75M utilized in FY25. Even with $240M on the balance sheet, the company has roughly 2.5 years of runway before needing to return to the ATM or debt markets.
⚖️ Verdict: ⚪
Neutral. Management executed perfectly on the operational goals: massive volume growth and Medicare coverage. However, the financial reality of this 'Win-in-MRD' strategy is a highly capital-intensive scale-up phase that will drag on profitability throughout 2026.
Key Themes
Medicare Coverage Catalysts Achieved
The single most important leading indicator for Personalis was securing Medicare reimbursement. Management delivered coverage for breast cancer surveillance in Q4 and announced Stage I-III NSCLC coverage effective Q1 2026. This validates the clinical utility demonstrated in the TRACERx and VHIO studies and opens the tap for an expected 5x surge in clinical revenue ($10-11M) in 2026.
Clinical Volume Accelerating Rapidly
The adoption curve for NeXT Personal is aggressively accelerating. Q4 volume reached 6,183 tests, a 41% sequential jump from Q3. The company expects to deliver 43,000 to 45,000 tests in 2026, roughly 2.7x the 2025 total. This aggressive pre-reimbursement land-grab, supported by the Tempus AI partnership, is successfully building a massive installed physician base.
Gross Margin Decimation from Subsidized Tests
The cost of building market share is evident in the margins. The company is actively choosing to absorb the cost of unreimbursed tests to drive physician adoption. Consequently, FY26 gross margin is guided to a poor 15% to 20%. While management frames this as a 'strategic decision,' it fundamentally weakens the income statement until broader private payer coverage is secured.
Legacy Business Acting as a Drag
While clinical volume surges, legacy segments continue to decelerate. Enterprise sales (Natera) and population sequencing (VA MVP) fell from $25.4M in 2024 to $17.6M in 2025, and are guided down further to ~$13.0M in 2026. This secular decline forces the clinical diagnostics segment to run even faster just to keep total company revenue growing.
Accelerating Cash Burn Requires Monitoring
Management expects cash usage to accelerate to ~$100M in FY26 (up from an estimated ~$75M in FY25) to fund commercial expansion. To prepare, the company heavily utilized its At-The-Market (ATM) facility in 2025, raising $109M and diluting shareholders significantly (weighted-average shares rose from 59.3M to 89.2M YoY). While the $240M cash balance is solid, the widening $105M projected net loss leaves little room for execution missteps.
Other KPIs
Stable. Down slightly from $50.9M in FY24, missing the original FY25 guidance range of $52-$58M laid out earlier in the year. The biopharma translational research spending environment remains lumpy and continues to mask the underlying growth in the company's MRD initiatives.
Accelerating. Up significantly from $185M in Q1 2025, entirely driven by the aggressive $109M net proceeds raised via the ATM facility at an average price of $8.43. This provides the war chest required to absorb the guided $100M cash burn in FY26.
Guidance
Reversing. After declining 18% in FY25 (from $84.6M to $69.6M), total revenue is guided to return to growth (~13% YoY at the midpoint). This marks the inflection point where clinical revenue growth finally overtakes the legacy business runoff.
Accelerating. Implies roughly 5x growth over FY25's $2.0M. This validates the monetization phase of the 'Win-in-MRD' strategy, driven by the operationalization of the new Medicare coverage wins for breast and lung cancer.
Accelerating (Negatively). Widening significantly from the $81.3M loss in FY25. This reflects the intense upfront commercial investments and cost-of-goods scale-up required to deliver 43k-45k clinical tests before widespread commercial payer coverage is achieved.
Decelerating. A stark drop from the 30%+ levels enjoyed in early 2024. Management explicitly notes this reflects the strategic decision to absorb costs to build market share ahead of full reimbursement.
Key Questions
Margin Trough and Recovery
With gross margins guided down to 15-20% for 2026, what specific volume threshold or payer coverage milestones are required to return to the 40-50% gross margin profile originally targeted?
Commercial Payer Strategy
Now that Medicare coverage is secured for Breast and NSCLC, what is the timeline and strategy for converting major commercial payers, and how much of the 43,000-45,000 guided volume will fall under commercial lives?
Tempus Partnership ROI
Given the accelerating cash burn to support commercial expansion, how is the Tempus AI partnership evolving, and what specific percentage of the 2026 volume growth is expected to be generated by the Tempus salesforce versus the internal team?
Pharma Revenue Stability
Pharma testing revenue missed earlier FY25 guidance estimates. Is the $55-$56M projection for FY26 fully de-risked, or do you still see volatility and project push-outs in the biopharma sector?